Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 12/20 | 0.65 |
| ▸ | METAP1 | P53582 | 6/20 | 0.65 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7354565 | 0.99 | METAP2 (0.64) | METAP2METAP1LTA4HF10 | |
| SCHEMBL7358037 | 0.88 | METAP2 (0.70) | METAP2METAP1 | |
| SCHEMBL3999277 | 0.88 | F10 (0.50) | METAP2METAP1LTA4HF10 | |
| SCHEMBL25858386 | 0.88 | METAP2 (0.51) | METAP2METAP1LTA4HF10 | |
| SCHEMBL14984965 | 0.88 | LTA4H (0.52) | METAP2METAP1LTA4HF10 | |
| Hydrochloric Acid SCHEMBL7353872 | 0.87 | METAP2 (0.69) | METAP2METAP1 | |
| SCHEMBL7362110 | 0.87 | METAP2 (0.65) | METAP2METAP1 | |
| SCHEMBL19350607 | 0.86 | METAP2 (0.49) | METAP2METAP1LTA4HF10 | |
| SCHEMBL12022090 | 0.86 | METAP2 (0.49) | METAP2METAP1LTA4HF10 | |
| Hydrochloric Acid SCHEMBL7361219 | 0.86 | METAP2 (0.64) | METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | claimed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | claimed |
| US-20110294952-A1 | Optimized Drug Conjugates | SynDevRX (US) | 2011-12-01 | — | — | US | disclosed |
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | disclosed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294952-A1 | Optimized Drug Conjugates | ABCB1, ABCG2, UGT1A3 | METAP2 2243/4885METAP1 1935/4885LTA4H 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.